Surgery

TISSEEL [Fibrin Sealant]

TISSEEL

Surgeons rely on TISSEEL offering hemostasis and sealing. With a 40-year proven history of clinical safety and efficacy, TISSEEL can reach bleeding in sites inaccessible to "surgical" means (i.e., sutures and cautery) . TISSEEL can help address bleeding as an adjunct hemostat across many surgical specialties and is also clinically proven to be effective in sealing during challenging colostomy procedures.

Indications

Hemostasis: TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients.

Sealing: TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies.

Important Risk Information

For Topical Use Only. Do not inject TISSEEL directly into the circulatory system or into highly vascularized tissue. Intravascular application of TISSEEL can lead to intravascular coagulation, can result in life-threatening thromboembolic events, and can increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients. To minimize the risk of intravascular application, exercise caution when using TISSEEL in surgery.

Do not use TISSEEL in individuals with a known hypersensitivity to aprotinin.

Do not use TISSEEL for treatment of severe or brisk arterial or venous bleeding. In these situations, TISSEEL will be washed away in the flow of blood before hemostasis can be attained.

Do not spray TISSSEEL where the minimum recommended distance from the applicator tip to the target site cannot be assured.

Hypersensitivity or allergic/anaphylactoid reactions can occur with the use of TISSEEL. Such reactions may especially be seen if TISSEEL is applied repeatedly over time or in the same setting, or if systemic aprotinin has been administered previously.

Aprotonin is known to be associated with anaphylactic reactions. Even in the case of strict local application of aprotinin, there is a risk of anaphylactic reactions to aprotinin, particularly in the case of previous exposure.

Discontinue administration of TISSEEL in the event of hypersensitivity reactions. Remove remaining product from the application site.

Air or gas embolism has occurred when fibrin sealant was administered using pressurized gas. This can occur if a spray device is used at higher than recommended pressures and in closer than recommended proximity to the tissue surface.

When using the EASYSPRAY device, or an equivalent spray device for open surgical procedures cleared by FDA, TISSEEL must not be sprayed in enclosed body areas and must be sprayed onto only visible application sites.

TISSEEL is denatured when exposing to solutions containing alcohol, iodine or heavy metals. If any of these substances have been used to clean the wound area, the area must be thoroughly rinsed before the application of TISSEEL.

Apply TISSEEL as a thin layer by dripping or spraying using cannula or spray set. Excess clot thickness can negatively interfere with wound healing.

The safety and effectiveness of TISSEEL used alone or in combination with biocompatible carriers in neurosurgical procedures or other surgeries involving confined spaces have not been evaluated; its use in this setting is not FDA approved.

TISSEEL is made from human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.


For more information, please visit www.tisseel.com.



global-footer








# About Baxter /sites/baxter/inside-baxter/about/overview/corporate.page Corporate Overview /baxter/inside-baxter/about/overview/corporate.page Science & Innovation /baxter/inside-baxter/science/innovations/past-present-future.page Careers /baxter/careers.page Investors http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-irhome Corporate Responsibility /baxter/corporate-responsibility.page News & Media /baxter/news-media.page Our Products & Expertise /baxter/all-products.page Overview /baxter/products-expertise/overview.page Acute Therapies /baxter/products-expertise/renal-failure-treatments/acute-therapies-overview.page Dialysis /baxter/products-expertise/renal-failure-treatments/dialysis-overview.page IV/Infusion /baxter/products-expertise/iv-infusion-systems/overview.page Nutrition /baxter/products-expertise/parenteral-nutrition/overview.page Surgery /baxter/products-expertise/advanced-surgery/overview.page Contract Manufacturing /baxter/products-expertise/contract-manufacturing.page Material Safety Data Sheet https://baxter.gensuite.com/Baxter/ehs/msds/index.cfm?Org=External%20Search&loc=Baxter%20Customer%20SDS%20Search&pagetype=basic&scopeappconfigid=3&passCode=2F5BD4299C7C708F16122F8BEE1C0183 Authorized Distributor of Record /assets/downloads/2015/Baxter - ADR List Jun 11 2015.pdf Contact & Support /baxter/contact-and-support/contact.page Contact /baxter/contact-and-support/contact.page Product Catalog http://ecatalog.baxter.com/ecatalog/home.html?cid=20016&lid=10001&hid=20001 eServices Center https://eservices.baxter.com/csse1/welcome.html Sitemap /baxter/sitemap.page Privacy at Baxter /baxter/privacy.page Copyright & Legal Disclaimers /baxter/copyright-legal-disclaimer.page Linking Disclaimers /baxter/linking-disclaimer.page Web Accommodations /baxter/web-accessibility.page Cybersecurity /baxter/cybersecurity.page linkedin LinkedIn https://www.linkedin.com/company/baxter-healthcare?WT.svl=www.baxter.com twitter Twitter https://twitter.com/baxter_intl?WT.svl=www.baxter.com facebook Facebook https://www.facebook.com/BaxterInternationalInc/?fref=ts youtube YouTube https://www.youtube.com/user/BaxterInternational?WT.svl=www.baxter.com rss RSS /baxter/news-media/newsroom/RSS-link.page email email http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-alerts 2017
USMP/81/17-0008 true Keep up with Baxter [$WSSP] = [80] [Host] = [www.baxter.com] [$WSSN] = [www.baxter.com] [User-Agent] = [Mozilla/5.0 (compatible; bingbot/2.0; +http://www.bing.com/bingbot.htm)] [$WSSC] = [http] [$WSRH] = [207.46.13.89] [Cache-Control] = [no-cache] [Pragma] = [no-cache] [$WSIS] = [false] [Surrogate-Capability] = [WS-ESI="ESI/1.0+"] [$WSRA] = [207.46.13.89] [_WS_HAPRT_WLMVERSION] = [-1] [Accept-Encoding] = [gzip, deflate] [$WSPR] = [HTTP/1.1] [Accept] = [*/*] [From] = [bingbot(at)microsoft.com] products-expertise/renal-failure-treatments/acute-therapies-overview iw/config/asset-list.xml iw/config/asset-list.xsl